Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: The Japan post-Marketing Alteplase Registration Study (J-MARS)

Stroke

Volumn 41, Issue 9, 2010, Pages 1984-1989

  Nakagawara, Jyoji ^a   Minematsu, Kazuo ^b   Okada, Yasushi ^c   Tanahashi, Norio ^d   Nagahiro, Shinji ^e   Mori, Etsuro ^f   Shinohara, Yukito ^g   Yamaguchi, Takenori ^b  

^a Nakamura Memorial Hospital   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^d SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^e UNIVERSITY OF TOKUSHIMA   (Japan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

Author keywords

acute ischemic stroke; alteplase; postmarketing registration; thrombolysis; tissue plasminogen activator

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; TREATMENT OUTCOME; CLINICAL TRIAL; JAPAN; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROCEDURES; REGISTER; STROKE; TIME;

AGED; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; JAPAN; MALE; MIDDLE AGED; REGISTRIES; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77956410175     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.589606     Document Type: Article

References (22)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
2. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38: 1655-1711.
3. The European Stroke Initiative Executive Committee and European Stroke Initiative Writing Group. European stroke initiative recommendations for stroke management\update 2003. Cerebrovasc Dis. 2003; 16:311-337.
4. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick J, Brott T, Frankel M, Grotta J, Haley EJ, Kwiatkowski T, Levine S, Lewandowski C, Lu M, Lyden P, Marler J, Patel S, Tilley B, Albers G, Bluhmki E, Wilhelm M, Hamilton S. ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
5. Hacke W, Kaste M, Fieshchi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M. (for the ECASS Study Group). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995;274: 1017-1025.
6. Hacke W, Kaste M, Fieshchi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnon G, Schneider D, Diez-Tejedor E, Trouillas P. (Second European-Australasian Acute Stroke Study Investigators). Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
7. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282: 2019-2026.
8. Clark WM, Albers GW, Madden KP, Hamilton S. Thert PA (alteplase) 0-to 6-hour acute stroke trial, part A (A0276g): results of a doubleblind, placebo-controlled, multicenter study. Thrombolytic therapy in acute is-chemic stroke study investigators. Stroke. 2000;31:811-816.
9. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y, the Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37:1810-1815.
10. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A. Intravenous recombinant tissue plasmino-gen activator in acute carotid artery territory stroke. Neurology. 1992;42: 976-982.
11. Yamaguchi T, Hayakawa T, Kiuchi H, for the Japanese Thrombolysis Study Group. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis. 1993;3: 269-272.
12. Yamaguchi T, Kikuchi H, Hayakawa T, for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasmin-ogen activator in acute embolic stroke: a randomized, double-blind, dose-comparison study of duteplase. In: Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ, eds. Thrombolytic Therapy in Acute Ische-mic Stroke III. Tokyo, Japan: Springer-Verlag; 1995:223-229.
13. Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T. Effect of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion\Japan Alteplase Clinical Trial II. Stroke. 2010;41:461-465.
14. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007; 369:275-282.
15. Guideline Committee for intravenous rt-PA (alteplase) in acute ischemic stroke: guidelines for intravenous application of rt-PA (alteplase). Jpn J Stroke. 2005;26:327-354.
16. Shinohara Y, Yamaguchi T. Outline of the Japanese Guidelines for the Management of Stroke 2004 and subsequent revision. Int J Stroke. 2008; 3:55-62.
17. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-1150.
18. Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005;172: 1307-1312.
19. Wardlaw JM, del Zoppo G, Yamaguchi T. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2000;2:CD000213.
20. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;3:CD000213.
21. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32: 438-441.
22. Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Okada Y, Hasegawa Y, Kario K, Okuda S, Nishiyama K, Minematsu K, for the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) Study Investigators. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients. General outcomes and prognostic factors from the SAMURAI Register. Stroke. 2009;40:3591-3595.